|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Johnson & Johnson recently wrapped up a months-long process to review its creative agencies.
GlaxoSmithKline spiked to a five-week high after it became the second company this week to dump its bid for Pfizer's consumer health care business.
AbbVie's key lung cancer candidate, Rova-T falls short in a phase II study, J&J gets buyout offer for its LifeScan unit from private firm, Platinum Equity.
Bloomberg's Ed Hammond discusses Pfizer Inc.'s attempt to unload its consumer-health business. He speaks with Bloomberg's Lisa Abramowicz on "Bloomberg Markets." (Source: Bloomberg)
GlaxoSmithKline (GSK.L) has quit the race to buy Pfizer's (PFE.N) consumer healthcare business, endangering an auction the U.S. drugmaker hoped would bring in as much as 14.2 billion pounds. GlaxoSmithKline (GSK), which announced its withdrawal on Friday, was seen as the frontrunner to buy the assets after Reckitt Benckiser (RB.L) left the race late on Wednesday. "While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation," GSK Chief Executive Emma Walmsley said in a statement.
GlaxoSmithKline, Reckitt Benckiser and Johnson & Johnson have each decided not to pursue a deal.
In December 2017, Teva Pharmaceutical (TEVA) laid down its restructuring plan, which included R&D (research and development) optimization involving the consolidation of its R&D sites while maintaining a robust R&D portfolio. For more details, read What’s Teva Pharmaceutical’s Research and Development Strategy? Since Teva laid out its restructuring plans, it has cut down 25 of its specialty area projects, representing ~27% of its R&D programs.
A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.
There are a number of reasons that attract investors towards large-cap companies such as Pfizer Inc (NYSE:PFE), with a market cap of US$215.76B. Big corporations are much sought after byRead More...
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
The Dow traversed rough water once again this week, marked by troubles for Facebook, Inc. (FB) and the Fed's latest policy statement.
Investor Update: How Is Teva's Restructuring Plan Progressing? Teva Pharmaceutical (TEVA) announced a restructuring plan in mid-December 2017. The announcement came after the company made some key leadership changes to recuperate from the dismal performance it saw over the last few quarters following its acquisition of Allergan’s (AGN) generics business and the negative impact of increasing generics business competition and pricing pressures.
Among the companies with shares expected to trade actively in Friday's session are Boeing, Alphabet, Facebook, Dropbox, Kroger, Nike and Micron.
Mar.23 -- Bloomberg's Ed Hammond discusses Pfizer Inc.'s attempt to unload its consumer-health business. He speaks with Bloomberg's Lisa Abramowicz on "Bloomberg Markets."
GlaxoSmithKline has declined to put in a final bid to buy Pfizer's consumer healthcare business, endangering an auction the U.S. drugmaker hoped would bring in as much as $20 billion. Kate King reports.